Cervical Cancer
MK2870-036: A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as First-line Maintenance Treatment for Participants With Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1 (TroFuse 036/GOG-3123/ENGOT-cx22)
- Details
ClinicalTrials.gov ID:
NCT07216703
Diagnosis Type:
NA
USOR Number:
- Address
,
P: